Events

Videos

Podcasts

Articles

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Sequencing of Therapy in Refractory mCRC

Management of Side Effects With TAS-102

Proactive Side Effect Management With Regorafenib

Clinical Implications of the ReDOS Findings

The Regorafenib Dose Optimization Study

Treatment Options in Refractory mCRC

Treatment Goals in Refractory mCRC

The addition of pembrolizumab to stereotactic body radiotherapy induced an objective response rate of 13.2% among patients with advanced solid tumors.

Pembrolizumab Plus SBRT Active in Advanced Solid Tumors

A panel of several of the world’s foremost experts on immunotherapy in lung cancer discuss durvalumab and other emerging approaches for stage III NSCLC.

Immunotherapy Poised to Move Forward Into Stage III NSCLC

Sagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses the safety profile of immunotherapy in combination with radiation in the treatment of patients with lung cancer.
 

Dr. Sampath on Safety of Immunotherapy Plus Radiation in Lung Cancer

Joaquim Bellmunt, MD, PhD, discusses the updated pembrolizumab findings, as well as the future of immunotherapy in bladder cancer.

Pembrolizumab Update Solidifies Survival Benefit in Bladder Cancer

Other Promising Targets in TNBC

Role of the Androgen Receptor in TNBC

Combination Therapy for TNBC: Checkpoint Inhibitor + Chemotherapy

Checkpoint Inhibitor Monotherapy for TNBC

Antibody-Drug Conjugates in Treating TNBC

Paclitaxel vs Nab-Paclitaxel in Metastatic TNBC

No pCR in Patients After Neoadjuvant Chemotherapy in TNBC

Anthracycline-Based Regimens: Perioperative Setting for TNBC

Neoadjuvant Therapy in TNBC

Immuno-Oncology

Immuno-Oncology | Specialty